Covalent Group, Inc. (Nasdaq: CVGR), a leader in the design,
development, and management of complex clinical trials and patient
registries for many of the world's leading pharmaceutical and
biotechnology companies, announced today the signing of multiple
Phase 1 and Phase 2 contracts having an aggregate value of $8.2
million. All of the contracts are with the same client and relate
to the development of a potentially important agent to treat
multiple types of influenza, including Avian Flu. Services include
consulting on clinical trial design and protocol development,
project and study site management, field operations, data
management, and biostatistical support. Revenue recognition began
during the recently completed third quarter and will continue on a
proportional performance basis over the life of the contract as
services are performed. Kenneth M. Borow, M.D., Chief Executive
Officer and President for Covalent Group, commented, �We are
exceptionally proud of our involvement in this important
development program which we believe could ultimately prove to be
beneficial to millions of people worldwide. These contract wins
were the result of highly coordinated business development and
clinical operations efforts on the part of Covalent Group and
Remedium Oy, a privately owned, full-service contract research
organization (CRO) based in Espoo, Finland that we expect to
acquire. The closing of the Remedium transaction is targeted for
November 1, 2006 and is subject to the approval of our
shareholders. We believe that these contract wins represent a
strong proof-of-concept that the combination of Covalent and
Remedium, resulting in the newly created company Encorium Group,
Inc. (�Encorium�), will be a highly competitive force in the drug
development and CRO marketplaces. Our belief is supported by the
fact that patient recruitment for the Phase 2 studies included in
the current contracts is expected to occur in North America,
Scandinavia, the Baltics, and Western, Central and Eastern Europe.
Encorium will have operational capabilities in all of these regions
on a post-acquisition basis.� Dr. Borow continued, �With this
announcement, the net value of Covalent�s signed new business
year-to-date is $22.8 million, an increase of approximately 20%
compared to our 12-month total of $19.1 million for 2005. With
these new contracts, Covalent�s backlog is in excess of $35
million, an increase of more than 50% since December 31, 2005. This
ongoing success in winning new contracts adds further support to
our value-proposition that provides integrated consulting and
operational services to companies for the development of products
that have the potential to make a difference in global healthcare.�
Dr. Borow concluded, �We expect our third quarter 2006 net revenues
will be in the range of $3.6-$3.7 million. Given our current cost
structure, we expect that net income for the quarter will be in the
range of $625,000-$675,000. This will be Covalent Group�s second
consecutive quarter of profitable operations and will make the
Company profitable for the nine months ended September 30, 2006.
Our cash flow from operations during the third quarter was very
strong and we ended the quarter with approximately $8.7 million in
cash, an increase of $1.6 million from the end of 2005.� About
Covalent Group, Inc. Covalent Group, Inc. is a clinical research
organization that is a leader in the design and management of
complex clinical trials and Patient Disease Registries for the
pharmaceutical, biotechnology and medical device industries. The
Company�s mission is to provide its clients with high quality,
full-service support for their biopharmaceutical development
programs. Covalent offers therapeutic expertise, experienced team
management and advanced technologies. The Company has drug and
biologics development as well as clinical trial experience across a
wide variety of therapeutic areas such as cardiovascular,
endocrinology/metabolism, diabetes, vaccines, infectious diseases,
gene therapy, immunology, neurology, oncology, gastroenterology,
dermatology, hepatology, women�s health and respiratory medicine.
Covalent believes that its leadership in the design of complex
clinical trials, its therapeutic expertise and commitment to
excellence, and its application of innovative technologies, offer
its clients a means to more quickly and cost effectively move
products through the clinical development process. With its
wholly-owned international subsidiary, Covalent Group, Ltd.,
Covalent is able to meet the North American and Western European
drug development needs of its clients. For more information, please
visit www.covalentgroup.com. This press release contains
forward-looking statements identified by words such as �estimate,�
�project,� �expect,� �intend,� �believe,� �anticipate� and similar
expressions. Actual results might differ materially from those
projected in, expressed in or implied by the forward-looking
statements. Potential risks and uncertainties that could affect the
Company's future operating results and financial condition include,
without limitation: (i) our success in attracting new business and
retaining existing clients and projects; (ii) the size, duration,
and timing of clinical trials we are currently managing may change
unexpectedly; (iii) the termination, delay or cancellation of
clinical trials we are currently managing could cause revenues to
decline unexpectedly; (iv) the timing difference between our
receipt of contract milestone or scheduled payments and our
incurring costs to manage these trials; (v) outsourcing trends in
the pharmaceutical, biotechnology and medical device industries;
(vi) the ability to maintain profit margins in a competitive
marketplace; (vii) our ability to attract and retain qualified
personnel; (viii) the sensitivity of our business to general
economic conditions; (ix) other economic, competitive, governmental
and technological factors affecting our operations, markets,
products, services and prices; (x) announced awards received from
existing and potential customers are not definitive until fully
negotiated contracts are executed by the parties;(xi) our backlog
may not be indicative of future revenues and may not generate the
revenues expected;(xii) our ability to successfully integrate the
businesses of Covalent and Remedium and (xiii) the performance of
the combined business to operate successfully and generate growth.
You should not place any undue reliance on these forward looking
statements which speak only as of the date of this press release.
Additional information concerning factors that might affect our
business or stock price which could cause actual results to
materially differ from those in forward-looking statements is
contained in Covalent Group's SEC filings, including its Annual
Report on Form 10-K for the year ended December 31, 2005 and other
periodic reports under the Securities Exchange Act of 1934, as
amended, copies of which are available upon request from Covalent
Group's investor relations department or The Equity Group Inc.
Covalent Group, Inc. (Nasdaq: CVGR), a leader in the design,
development, and management of complex clinical trials and patient
registries for many of the world's leading pharmaceutical and
biotechnology companies, announced today the signing of multiple
Phase 1 and Phase 2 contracts having an aggregate value of $8.2
million. All of the contracts are with the same client and relate
to the development of a potentially important agent to treat
multiple types of influenza, including Avian Flu. Services include
consulting on clinical trial design and protocol development,
project and study site management, field operations, data
management, and biostatistical support. Revenue recognition began
during the recently completed third quarter and will continue on a
proportional performance basis over the life of the contract as
services are performed. Kenneth M. Borow, M.D., Chief Executive
Officer and President for Covalent Group, commented, "We are
exceptionally proud of our involvement in this important
development program which we believe could ultimately prove to be
beneficial to millions of people worldwide. These contract wins
were the result of highly coordinated business development and
clinical operations efforts on the part of Covalent Group and
Remedium Oy, a privately owned, full-service contract research
organization (CRO) based in Espoo, Finland that we expect to
acquire. The closing of the Remedium transaction is targeted for
November 1, 2006 and is subject to the approval of our
shareholders. We believe that these contract wins represent a
strong proof-of-concept that the combination of Covalent and
Remedium, resulting in the newly created company Encorium Group,
Inc. ("Encorium"), will be a highly competitive force in the drug
development and CRO marketplaces. Our belief is supported by the
fact that patient recruitment for the Phase 2 studies included in
the current contracts is expected to occur in North America,
Scandinavia, the Baltics, and Western, Central and Eastern Europe.
Encorium will have operational capabilities in all of these regions
on a post-acquisition basis." Dr. Borow continued, "With this
announcement, the net value of Covalent's signed new business
year-to-date is $22.8 million, an increase of approximately 20%
compared to our 12-month total of $19.1 million for 2005. With
these new contracts, Covalent's backlog is in excess of $35
million, an increase of more than 50% since December 31, 2005. This
ongoing success in winning new contracts adds further support to
our value-proposition that provides integrated consulting and
operational services to companies for the development of products
that have the potential to make a difference in global healthcare."
Dr. Borow concluded, "We expect our third quarter 2006 net revenues
will be in the range of $3.6-$3.7 million. Given our current cost
structure, we expect that net income for the quarter will be in the
range of $625,000-$675,000. This will be Covalent Group's second
consecutive quarter of profitable operations and will make the
Company profitable for the nine months ended September 30, 2006.
Our cash flow from operations during the third quarter was very
strong and we ended the quarter with approximately $8.7 million in
cash, an increase of $1.6 million from the end of 2005." About
Covalent Group, Inc. Covalent Group, Inc. is a clinical research
organization that is a leader in the design and management of
complex clinical trials and Patient Disease Registries for the
pharmaceutical, biotechnology and medical device industries. The
Company's mission is to provide its clients with high quality,
full-service support for their biopharmaceutical development
programs. Covalent offers therapeutic expertise, experienced team
management and advanced technologies. The Company has drug and
biologics development as well as clinical trial experience across a
wide variety of therapeutic areas such as cardiovascular,
endocrinology/metabolism, diabetes, vaccines, infectious diseases,
gene therapy, immunology, neurology, oncology, gastroenterology,
dermatology, hepatology, women's health and respiratory medicine.
Covalent believes that its leadership in the design of complex
clinical trials, its therapeutic expertise and commitment to
excellence, and its application of innovative technologies, offer
its clients a means to more quickly and cost effectively move
products through the clinical development process. With its
wholly-owned international subsidiary, Covalent Group, Ltd.,
Covalent is able to meet the North American and Western European
drug development needs of its clients. For more information, please
visit www.covalentgroup.com. This press release contains
forward-looking statements identified by words such as "estimate,"
"project," "expect," "intend," "believe," "anticipate" and similar
expressions. Actual results might differ materially from those
projected in, expressed in or implied by the forward-looking
statements. Potential risks and uncertainties that could affect the
Company's future operating results and financial condition include,
without limitation: (i) our success in attracting new business and
retaining existing clients and projects; (ii) the size, duration,
and timing of clinical trials we are currently managing may change
unexpectedly; (iii) the termination, delay or cancellation of
clinical trials we are currently managing could cause revenues to
decline unexpectedly; (iv) the timing difference between our
receipt of contract milestone or scheduled payments and our
incurring costs to manage these trials; (v) outsourcing trends in
the pharmaceutical, biotechnology and medical device industries;
(vi) the ability to maintain profit margins in a competitive
marketplace; (vii) our ability to attract and retain qualified
personnel; (viii) the sensitivity of our business to general
economic conditions; (ix) other economic, competitive, governmental
and technological factors affecting our operations, markets,
products, services and prices; (x) announced awards received from
existing and potential customers are not definitive until fully
negotiated contracts are executed by the parties;(xi) our backlog
may not be indicative of future revenues and may not generate the
revenues expected;(xii) our ability to successfully integrate the
businesses of Covalent and Remedium and (xiii) the performance of
the combined business to operate successfully and generate growth.
You should not place any undue reliance on these forward looking
statements which speak only as of the date of this press release.
Additional information concerning factors that might affect our
business or stock price which could cause actual results to
materially differ from those in forward-looking statements is
contained in Covalent Group's SEC filings, including its Annual
Report on Form 10-K for the year ended December 31, 2005 and other
periodic reports under the Securities Exchange Act of 1934, as
amended, copies of which are available upon request from Covalent
Group's investor relations department or The Equity Group Inc.
Covalent (NASDAQ:CVGR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Covalent (NASDAQ:CVGR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024